市場調査レポート
商品コード
1428328

次世代抗体医薬品の世界市場レポート 2024

Next-Generation Antibody Therapeutics Global Market Report 2024

出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.49円
次世代抗体医薬品の世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2~10営業日
ご注意事項 :
本レポートの納品は、最新情報反映のため受注時に適宜更新しお届けいたします。
更新情報の反映作業にあたり納期もレポート毎に異なりますので、ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

次世代抗体医薬品の市場規模は、今後数年間で急速に成長すると予想されています。 2028年には10.8%の年間複合成長率(CAGR)で104億1,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、バイオシミラー開発、二重特異性抗体の開発、ナノボディ開発、患者中心のアプローチ、免疫調節抗体の利用、自己免疫疾患における用途の拡大、および連続製造の採用に起因すると考えられます。予測期間の主な動向には、抗体工学の進歩、抗体設計におけるデジタル技術の統合、業界連携、ドラッグデリバリーシステムの進歩、抗体開発におけるリアルワールドエビデンス(RWE)の使用が含まれます。

予想される慢性疾患の有病率の増加は、次世代抗体医薬品市場の成長を促進する態勢が整っています。慢性疾患は1年以上続くため、継続的な治療が必要となり、日常生活が制限されることがよくあります。 次世代抗体医薬品は、慢性疾患を持つ個人に的を絞ったケアを提供する上で極めて重要な役割を果たし、患者の転帰の改善に貢献します。 2023年 1月の国立バイオテクノロジー情報センター(NCBI)の予測によると、少なくとも1つの慢性疾患を持つ50歳以上の人の数は2050年までに99.5%増加し、1億4,266万人に達すると予想されています。これは、慢性疾患の蔓延に対処する上で次世代抗体医薬品が極めて重要な役割を果たしていることを強調しています。

製薬会社の需要の高まりにより、次世代抗体医薬品市場の成長が促進されると考えられます。製薬産業は、創薬、開発、生産、マーケティングに重点を置き、ヘルスケアにおいて重要な役割を果たしています。 次世代抗体医薬品は、ターゲティング精度の向上、副作用の軽減、個別化医療、半減期の延長、投与間隔の革新、多機能抗体、製造プロセスの最適化などの利点を提供します。 2023年 6月、欧州製薬産業協会連合(EFPIA)は、2022年の欧州の医薬品総生産額が3,842億米ドル(3,400億ユーロ)に達し、2021年から4.95%増加したと報告しました。これは製薬会社に対する需要の増大を裏付けており、それによって次世代抗体医薬品市場が牽引されています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 市場促進要因・市場抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 市場規模と成長実績、2018~2023年
  • 市場規模と成長予測、2023~2028年、2033年

第6章 市場セグメンテーション

  • 世界の次世代抗体医薬品市場、抗体タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • モノクローナル抗体
  • ポリクローナル抗体
  • 二重特異性抗体
  • 抗体薬物複合体(ADC)
  • その他
  • 世界の次世代抗体医薬品市場、治療領域別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 腫瘍
  • 自己免疫疾患
  • 感染症
  • 神経変性疾患
  • その他
  • 世界の次世代抗体医薬品市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院・クリニック
  • 研究機関
  • 製薬会社・バイオテクノロジー会社
  • その他

第7章 地域および国の分析

  • 世界の次世代抗体医薬品市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界の次世代抗体医薬品市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 次世代抗体医薬品市場の競合情勢
  • 次世代抗体医薬品市場の企業プロファイル
    • Pfizer Inc.
    • F. Hoffmann-La Roche Ltd.
    • Bayer AG
    • Bristol-Myers Squibb Company
    • AstraZeneca plc

第31章 その他の大手および革新的な企業

  • GlaxoSmithKline plc
  • Takeda Pharmaceutical Company Limited
  • Gilead Sciences Inc.
  • Boehringer Ingelheim International GmbH
  • Amgen Inc.
  • Moderna Inc.
  • BioNTech SE
  • Regeneron Pharmaceuticals Inc.
  • Biogen Inc.
  • Celgene Corporation
  • Lonza Group AG
  • Catalent Inc.
  • Genentech Inc.
  • Kyowa Hakko Kirin Co. Ltd.
  • Samsung Biologics

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r14172

Next-generation antibody therapeutics represent a class of advanced antibody-based drugs characterized by enhanced structures, functionalities, and therapeutic potential beyond traditional monoclonal antibodies. These therapeutics are employed to address severe medical conditions, including cancer, infectious infections, and immunological disorders.

The main types of antibodies in next-generation antibody therapeutics include monoclonal antibodies, polyclonal antibodies, biospecific antibodies, antibody-drug conjugates, and others. Monoclonal antibodies are laboratory-produced proteins designed to bind to specific targets, such as antigens on the surface of cancer cells. These therapeutics find applications across various therapeutic areas, including oncology, autoimmune diseases, infectious diseases, neurodegenerative disorders, and others. They are utilized in hospitals and clinics, research institutes, pharmaceutical and biotechnology companies, and other relevant entities.

The next-generation antibody therapeutics market research report is one of a series of new reports from The Business Research Company that provides next-generation antibody therapeutics market statistics, including next-generation antibody therapeutics industry global market size, regional shares, competitors with a next-generation antibody therapeutics market share, detailed next-generation antibody therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the next-generation antibody therapeutics industry. This next-generation antibody therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The next-generation antibody therapeutics market size has grown rapidly in recent years. It will grow from $6.14 billion in 2023 to $6.9 billion in 2024 at a compound annual growth rate (CAGR) of 12.4%. The expansion observed in the historical period can be attributed to the success of monoclonal antibodies, the increasing prevalence of chronic diseases, the approval of antibody-drug conjugates, and the growth of immunotherapy, gene therapy, and antibodies.

The next-generation antibody therapeutics market size is expected to see rapid growth in the next few years. It will grow to $10.41 billion in 2028 at a compound annual growth rate (CAGR) of 10.8%. The anticipated growth in the forecast period can be attributed to biosimilar development, the development of bispecific antibodies, nanobody development, patient-centric approaches, the utilization of immunomodulatory antibodies, expanded applications in autoimmune diseases, and the adoption of continuous manufacturing. Major trends in the forecast period include advancements in antibody engineering, the integration of digital technologies in antibody design, industry collaborations, advancements in drug delivery systems, and the use of real-world evidence in antibody development.

The anticipated rise in the prevalence of chronic diseases is poised to drive the growth of the next-generation antibody therapeutics market. Chronic diseases, enduring for a year or more, necessitate continuous medical care and often restrict daily activities. Next-generation antibody therapeutics play a pivotal role in offering targeted care for individuals with chronic illnesses, contributing to improved patient outcomes. As per projections from the National Center for Biotechnology Information (NCBI) in January 2023, the number of individuals aged 50 and older with at least one chronic illness is expected to surge by 99.5% by the year 2050, reaching 142.66 million. This underscores the pivotal role of next-generation antibody therapeutics in addressing the escalating prevalence of chronic diseases.

The increasing demand for pharmaceutical companies is set to propel the growth of the next-generation antibody therapeutics market. With a focus on drug discovery, development, production, and marketing, the pharmaceutical industry plays a crucial role in healthcare. Next-generation antibody therapeutics offer advantages such as improved targeting precision, reduced side effects, personalized medicine, extended half-life, dosage interval innovations, multifunctional antibodies, and optimized manufacturing processes. In June 2023, the European Federation of Pharmaceutical Industries and Associations (EFPIA) reported that the total pharmaceutical production in Europe reached $384,200 million (€340,000 million) in 2022, marking a 4.95% increase from 2021. This underscores the growing demand for pharmaceutical companies, thereby driving the next-generation antibody therapeutics market.

Technological advancements emerge as a key trend in the next-generation antibody therapeutics market. Major companies in the sector are focusing on creating technologically advanced products to fortify their market positions. An example is Merck KGaA's October 2021 launch of ChetoSensar, a technology addressing solubility issues and renewing hope for antibody-drug conjugates. ChetoSensar enhances the solubility of antibody-drug conjugates, expanding possibilities for developing next-generation therapeutic solutions.

Collaborations and partnerships are strategic trends gaining traction in the next-generation antibody therapeutics market. Such collaborations facilitate innovation, harness complementary expertise, and expedite the development and commercialization of advanced therapies. In December 2023, AbbVie Inc., a US-based pharmaceutical company, collaborated with BigHat Biosciences, a protein therapeutics company, to leverage machine learning (ML) and artificial intelligence (AI) for discovering therapeutic antibodies. This collaboration aims to advance the development of next-generation therapeutic antibodies through BigHat Biosciences' Milliner platform, combining ML technologies with a high-speed wet lab for antibody design and selection.

In October 2022, AbbVie, a US-based pharmaceutical company, acquired DJS Antibodies Ltd., a UK-based developer of therapeutic monoclonal antibodies. This strategic acquisition enhances AbbVie's antibody research initiatives, expands its immunology portfolio, and strengthens its position in Oxford's thriving bioscience sector.

Major companies operating in the next-generation antibody therapeutics market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Amgen Inc., Moderna Inc., BioNTech SE, Regeneron Pharmaceuticals Inc., Biogen Inc., Celgene Corporation, Lonza Group AG, Catalent Inc., Genentech Inc., Kyowa Hakko Kirin Co. Ltd., Samsung Biologics, WuXi Biologics, Seagen Inc., Seattle Genetics Inc., Xencor Inc., ImmunoGen Inc.

North America was the largest region in the next-generation antibody therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation antibody therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the next-generation antibody therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The next-generation antibody therapeutics market consists of revenues earned by entities by providing services such as antibody engineering, antibody manufacturing, and regulatory support. The market value includes the value of related goods sold by the service provider or included within the service offering. The next-generation antibody therapeutics market also includes sales of immune checkpoint inhibitors, antibody-targeted nanoparticles, and antibody-mimetic proteins. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Next-Generation Antibody Therapeutics Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on next-generation antibody therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for next-generation antibody therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The next-generation antibody therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Types Of Antibodies: Monoclonal Antibodies; Polyclonal Antibodies; Biospecific Antibodies; Antibody-Drug Conjugates; Other Types
  • 2) By Therapeutic Area: Oncology; Autoimmune Diseases; Infectious Diseases; Neurodegenerative Disorders; Other Therapeutic Areas
  • 3) By End-User: Hospitals And Clinics; Research Institutes; Pharmaceutical And Biotechnology Companies; Other End-Users
  • Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Bayer AG; Bristol-Myers Squibb Company; AstraZeneca plc
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Next-Generation Antibody Therapeutics Market Characteristics

3. Next-Generation Antibody Therapeutics Market Trends And Strategies

4. Next-Generation Antibody Therapeutics Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Next-Generation Antibody Therapeutics Market Size and Growth

  • 5.1. Global Next-Generation Antibody Therapeutics Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Next-Generation Antibody Therapeutics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Next-Generation Antibody Therapeutics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Next-Generation Antibody Therapeutics Market Segmentation

  • 6.1. Global Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Monoclonal Antibodies
  • Polyclonal Antibodies
  • Biospecific Antibodies
  • Antibody-Drug Conjugates
  • Other Types
  • 6.2. Global Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oncology
  • Autoimmune Diseases
  • Infectious Diseases
  • Neurodegenerative Disorders
  • Other Therapeutic Areas
  • 6.3. Global Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals And Clinics
  • Research Institutes
  • Pharmaceutical And Biotechnology Companies
  • Other End-Users

7. Next-Generation Antibody Therapeutics Market Regional And Country Analysis

  • 7.1. Global Next-Generation Antibody Therapeutics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Next-Generation Antibody Therapeutics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Next-Generation Antibody Therapeutics Market

  • 8.1. Asia-Pacific Next-Generation Antibody Therapeutics Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Next-Generation Antibody Therapeutics Market

  • 9.1. China Next-Generation Antibody Therapeutics Market Overview
  • 9.2. China Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Next-Generation Antibody Therapeutics Market

  • 10.1. India Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Next-Generation Antibody Therapeutics Market

  • 11.1. Japan Next-Generation Antibody Therapeutics Market Overview
  • 11.2. Japan Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Next-Generation Antibody Therapeutics Market

  • 12.1. Australia Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Next-Generation Antibody Therapeutics Market

  • 13.1. Indonesia Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Next-Generation Antibody Therapeutics Market

  • 14.1. South Korea Next-Generation Antibody Therapeutics Market Overview
  • 14.2. South Korea Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Next-Generation Antibody Therapeutics Market

  • 15.1. Western Europe Next-Generation Antibody Therapeutics Market Overview
  • 15.2. Western Europe Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Next-Generation Antibody Therapeutics Market

  • 16.1. UK Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Next-Generation Antibody Therapeutics Market

  • 17.1. Germany Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Next-Generation Antibody Therapeutics Market

  • 18.1. France Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Next-Generation Antibody Therapeutics Market

  • 19.1. Italy Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Next-Generation Antibody Therapeutics Market

  • 20.1. Spain Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Next-Generation Antibody Therapeutics Market

  • 21.1. Eastern Europe Next-Generation Antibody Therapeutics Market Overview
  • 21.2. Eastern Europe Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Next-Generation Antibody Therapeutics Market

  • 22.1. Russia Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Next-Generation Antibody Therapeutics Market

  • 23.1. North America Next-Generation Antibody Therapeutics Market Overview
  • 23.2. North America Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Next-Generation Antibody Therapeutics Market

  • 24.1. USA Next-Generation Antibody Therapeutics Market Overview
  • 24.2. USA Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Next-Generation Antibody Therapeutics Market

  • 25.1. Canada Next-Generation Antibody Therapeutics Market Overview
  • 25.2. Canada Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Next-Generation Antibody Therapeutics Market

  • 26.1. South America Next-Generation Antibody Therapeutics Market Overview
  • 26.2. South America Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Next-Generation Antibody Therapeutics Market

  • 27.1. Brazil Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Next-Generation Antibody Therapeutics Market

  • 28.1. Middle East Next-Generation Antibody Therapeutics Market Overview
  • 28.2. Middle East Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Next-Generation Antibody Therapeutics Market

  • 29.1. Africa Next-Generation Antibody Therapeutics Market Overview
  • 29.2. Africa Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Next-Generation Antibody Therapeutics Market Competitive Landscape And Company Profiles

  • 30.1. Next-Generation Antibody Therapeutics Market Competitive Landscape
  • 30.2. Next-Generation Antibody Therapeutics Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. F. Hoffmann-La Roche Ltd.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Bayer AG
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Bristol-Myers Squibb Company
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. AstraZeneca plc
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Next-Generation Antibody Therapeutics Market Other Major And Innovative Companies

  • 31.1. GlaxoSmithKline plc
  • 31.2. Takeda Pharmaceutical Company Limited
  • 31.3. Gilead Sciences Inc.
  • 31.4. Boehringer Ingelheim International GmbH
  • 31.5. Amgen Inc.
  • 31.6. Moderna Inc.
  • 31.7. BioNTech SE
  • 31.8. Regeneron Pharmaceuticals Inc.
  • 31.9. Biogen Inc.
  • 31.10. Celgene Corporation
  • 31.11. Lonza Group AG
  • 31.12. Catalent Inc.
  • 31.13. Genentech Inc.
  • 31.14. Kyowa Hakko Kirin Co. Ltd.
  • 31.15. Samsung Biologics

32. Global Next-Generation Antibody Therapeutics Market Competitive Benchmarking

33. Global Next-Generation Antibody Therapeutics Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Next-Generation Antibody Therapeutics Market

35. Next-Generation Antibody Therapeutics Market Future Outlook and Potential Analysis

  • 35.1 Next-Generation Antibody Therapeutics Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Next-Generation Antibody Therapeutics Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Next-Generation Antibody Therapeutics Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer